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Background: Owing to the number of genetic mutations that contribute to malformations of cortical development,
identification of causative mutations in candidate genes is challenging. To overcome these challenges, we performed
whole-exome sequencing in this study.
Case presentation: A Japanese patient presented with microcephaly and severe developmental delay. Brain magnetic
resonance imaging showed the presence of colpocephaly associated with lateral ventricle dilatation and the presence
of a simplified gyral pattern. Hypoplasia of the corpus callosum and cerebellar vermis were also noted. Because Sanger
sequencing is expensive, laborious, and time-consuming, whole-exome sequencing was performed and a de novo
missense mutation in TUBA1A (E27Q) was identified.
Conclusion: The novel mutation identified in this study was located in the genetic region that encodes the N-terminal
domain of TUBA1A, a region of TUBA1A with few reported mutations. Retrospective assessment of the clinical and
radiological features of this patient―i.e., microcephaly, lissencephaly (pachygyria) with cerebellar hypoplasia, and
corpus callosum hypoplasia―indicated that the TUBA1A mutation did not lead to any contradictions. Because rapid
and comprehensive mutation analysis by whole-exome sequencing is time- and cost-effective, it might be useful for
genetic counseling of patients with sporadic malformations of cortical development.
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Malformations of cortical development (MCD) are a cause
of motor and intellectual disabilities and severe epilepsy
[1]. Although various types of MCD have been described,
the most typical type is lissencephaly, a group of mal-
formations caused by abnormal neuronal migration [2].
The gene encoding platelet-activating factor acetylhydro-
lase isoform 1b regulatory subunit 1 (PAFAH1B1, formerly
LIS1) was initially identified as the causative gene of lis-
sencephaly. Advances in neuroradiological imaging and
genetic diagnosis have since improved our understanding
of the underlying pathogenesis of such diseases. Mutations* Correspondence: yamamoto.toshiyuki@twmu.ac.jp
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distribution, and reproduction in any mediumin tubulin genes, encoding tubulin alpha 1a (TUBA1A),
beta 2B class IIb (TUBB2B), and beta 3 class III (TUBB3),
are now recognized as major causes of MCD [3,4]. More-
over, the rapid development of new revolutionary molecu-
lar technologies has enabled us to identify rare genetic
variants in sporadic MCD cases [5].
In this study, we examined a Japanese patient with
sporadic MCD. As mentioned above, causative genes are
difficult to identify, owing to the large number of MCD
candidate genes. Sanger sequencing of potential causa-
tive genes is expensive, laborious, and time-consuming;
thus, we performed whole-exome sequencing. Using this
method, we identified a novel TUBA1A mutation. Here,
we discuss the advantages of using whole-exome sequen-
cing for the rapid detection of causative mutations and
genetic counseling of patients with sporadic MCD.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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Patient description
A Japanese baby girl was born at 41 weeks of gestation
with a birth weight of 3,400 g (+1.0 standard deviation
[SD]), length of 49.5 cm (+0.5 SD), and an occipito-
frontal circumference (OFC) of 31.5 cm (−1.0 SD). Her
Apgar score was 7/8 (1 min/5 min). Her 30-year-old
mother was gravida 0, para 0. At 22 weeks of gestation,
fetal microcephaly was detected by echosonography.
Soon after delivery, the sucking ability of the infant was
good despite mild muscle hypotonia. She showed marked
posterior sloping of the forehead, a high-arched palate,
and microretrognathia. At 6 days after birth, brain mag-
netic resonance imaging (MRI) revealed colpocephalic
configulation of the lateral ventricle dilatation associated
with a simplified gyral pattern (Figure 1).
The sucking ability of the infant gradually decreased;
at 2 months of age, tube feeding was initiated. At this
age, she weighed 4.7 kg (−0.8 SD) and measured 59.4 cm
(+1.2 SD) in length, with an OFC of 34.0 cm (−3.3 SD),
indicating severe microcephaly. She could not pursue
objects. Although her muscle tone was within normal
limits, she often showed an opisthotonic posture. At the
age of 3 months, brain MRI examination was performed
again, and brain hypoplasia associated with diffuse pa-
chygyria and lateral ventricle dilatation was found, which
is atypical for lissencephaly patients (Figure 1).
Conventional karyotyping revealed a normal female
karyotype with 46,XX. Because this child was the firstFigure 1 Brain magnetic resonance imaging of the patient. T2-weighte
indicate hypoplastic vermis of the cerebellum, cortical dysgenesis with a sim
(C and E) and T2-weighted (D and F) axial images at 3 months of age indic
ventricles. Cortical gyration is poor and reduced volume of the white matterborn, genetic counseling was provided and both parents
expressed a desire for their daughter to be genotyped.
We searched for the causative mutation(s) by whole-
exome sequencing by using a next generation sequencer.
After obtaining written informed consent, we obtained
blood samples from the patient and her biological par-
ents. This study was approved by the ethical committee
at Tokyo Women’s Medical University.
Whole-exome sequencing
Genomic DNA collected from the patient and her parents
were used as trio samples for whole-exome sequencing.
DNA was extracted using a QIAamp DNA extraction kit
(Qiagen, Hilden, Germany). Using a SureSelect whole
exon kit (Agilent Technologies, Santa Clara, CA), 3 μg of
DNA was processed according to the manufacturer’s ins-
tructions. Captured DNA molecules were analyzed using a
SOLiD3® system by paired-end analysis (Life Technologies,
Foster City, CA).
Color space reads were mapped to the UCSC hg19 ref-
erence genome using SOLiD® BioScope™ software (version
1.3; Life Technologies). Single-nucleotide variants (SNVs)
were subsequently called by the DiBayes algorithm using
medium call stringency. Small insertions and deletions
(indels) were detected using the SOLiD Small InDel Tool
(Life Technologies). Called SNVs and indels were filtered
based on depth and quality, combined, and the annotated
using ANNOVAR and a custom analysis pipeline [6]. Datad sagittal (A) and T1-weighted axial (B) images at 6 days after birth
plified gyral pattern, and dilatation of the lateral ventricles. T1-weighted
ate colpocephalic appearance associated with dilatation of the lateral
is apparent.
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(http://genome.ucsc.edu/).
As a priority, we focused only on non-synonymous
coding variants, splice acceptor and donor site muta-
tions, and frameshift indels. We extracted the candidate
variants that were not observed in the 1000 Genomes
Project (http://www.1000genomes.org/) and the dbSNP
132 database (http://www.ncbi.nlm.nih.gov/projects/
SNP/). Because we assumed that an autosomal domin-
ant trait existed in this family, variants identified only in
the proband, and not in the unaffected parents (de novo
variants), were selected. Missense mutations were tested
for mutational effects by using amino acid substitution
prediction tools such as PolyPhen-2 (http://genetics.bwh.
harvard.edu/pph2/) and SIFT (http://sift.jcvi.org/) [7,8].
The flow chart used to select candidate genes is shown
in Figure 2.
The potential genetic variants identified by whole-
exome sequencing were reconfirmed using standard poly-
merase chain reaction (PCR)-direct sequencing analysis
(Sanger sequencing), as described previously [9,10]. The
effects of the identified amino acid changes were analyzedFigure 2 Flow chart indicating the validation process for variants. Aftusing web-based software such as Pôle Bioinformatique
Lyonnais Network Protein Sequence Analaysis (http://
doua.prabi.fr/) and PSIPRED Protein Sequence Analysis
Workbench (http://bioinf.cs.ucl.ac.uk/psipred/).
Whole-exome sequencing generated an average of
223 × 106 mapped reads that could be mapped to the
reference genome—98% could be mapped accurately—
with a mean coverage of 93 (Table 1). After filtering, 1
indel and 15 SNVs remained for the de novo mutation
model (Table 2). For this model, the status of both parents
was required to define the wild-type state. No genetic vari-
ation remained for the X-linked recessive and autosomal
recessive models.
Among the 16 candidate variants in the de novo mu-
tation model, a TUBA1A variant, E27Q, was included.
The damaging effects of the variations were scored by
PolyPhen-2 and SIFT; the TUBA1A E27Q variant showed
a possible damaging effect. We considered the TUBA1A
variant as the strongest candidate mutation. Subsequent
Sanger sequencing confirmed the presence of this var-
iant in the proband and absence in the genomes of both
parents (Figure 3A). No variants in the other candidateer 5 steps of validation, 16 genetic variants are finally selected.
Table 1 Whole-exome sequencing output
Sample Proband Father Mother
Total reads 406,845,894 437,902,198 396,963,736
Mapped reads 252,829,848 214,184,732 201,932,294
Properly mapped reads 248,030,760 209,714,312 197,748,762




Total bases mapping to
target
5,449,744,981 4,422,564,459 4,033,208,506
Mean target coverage 109.336672 88.706873 81.004891
% target bases with ≥10x
coverage
85.51% 85.04% 83.56%
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cluded that MCD in this patient was the consequence of a
de novo mutation in TUBA1A. The risk of recurrence in
this family was estimated to be the same as that for the
general population.
Discussion
MCD is the consequence of abnormal neuronal mig-
ration, which results in intellectual impairment and
epilepsy [11]. Many of the genes responsible for MCD
are related to autosomal dominant traits caused by de
novo mutations—e.g., mutations in PAFAH1B1, TUBA1A,
TUBB2B, and TUBB3. However, some genes are related
to autosomal recessive MCD phenotypes, including the
genes encoding reelin (RELN), very-low-density lipopro-
tein receptor (VLDLR), tubulin alpha-8 (TUBA8), as well
as X-linked genes encoding doublecortin (DCX), aristaless
related homeobox (ARX), and filamin A alpha (FLNA)
[1,12,13]. Therefore, molecular diagnostic testing in pa-
tients with MCD is an important prerequisite for genetic
counseling, because the risk of recurrence cannot be esti-
mated in cases that lack a definitive molecular diagnosis.
In this study, we successfully identified a de novo
TUBA1A mutation in a patient with sporadic MCD using
whole-exome sequencing of trio samples. Among the
genes in the tubulin family, TUBA1A was the first to be
identified as a causative factor of MCD. The TUBA1A
protein is thought to function as a scaffold protein [14].
Although there are at least 34 known TUBA1A mu-
tations, and many of these mutations are located in the
C-terminal half of the amino acid sequence [3,11,14-27],
this report is the first to describe the E27Q mutation
(Additional file 1: Figure S1). In contrast to most of the
previously reported mutations, this mutation is located
in the N-terminal region (Additional file 1: Figure S1).
Because the mutation is located in a conserved region of
tubulin (Additional file 1: Figure S1), and the mutated
residue is conserved among many species (Figure 3B),we predicted that this mutation might be pathogenic.
We analyzed the effects of this mutation by using web-
based tools to predict the secondary structure of the mu-
tated protein. Of the two different computational simula-
tions, one predicted a significant change in the structure
of TUBA1A (Additional file 2: Figures S2 and Additional
file 3: Figure S3), suggesting that this mutation is likely
pathogenic.
Amino acid substitutions may affect heterodimer stabil-
ity and/or microtubule dynamics by altering the structure
of tubulin during nucleotide exchange and hydrolysis.
Microtubule stability may be diminished during the crit-
ical process of cell migration [28]. All mutations reported
thus far in TUBA1A, TUBB2B, and TUBB3 are heterozy-
gous missense mutations [3,4,29-31]. Missense mutations
in the absence of nonsense mutations, frameshifts, or gen-
omic deletions support altered protein function, rather
than haploinsufficiency, as the primary genetic etiology of
these tubulin-related disorders [28].
Retrospectively, we evaluated the MRI findings of this
patient. Brain MRI showed a colpocephalic appearance
of the lateral ventricle dilatation associated with a sim-
plified gyral pattern. Hypoplastic corpus callosum and
cerebellar vermis hypoplasia were also noted. According
to the classification proposed by Kumar et al. [11], lis-
sencephaly with cerebellar hypoplasia (LCH) in group 3
would be most compatible with this patient, because of
the involvement of the corpus callosum and cerebellum.
Ross et al. proposed genotype-phenotype correlations in
LCH cases encompassing heterogeneous disorders such
as those classified as LCH types a—d [32]. LCHa cases
are related to mutations in PAFAH1B1 or DCX, whereas
LCHb cases are linked to a mutation in RELN. Based on
the LCH pattern of the patient presenting microcephaly
(≤ − 3 SD), this case may be classified as LCHd, which
could be related to a mutation in TUBA1A. Therefore,
no contradiction in the etiology of the TUBA1A muta-
tion was observed.
Generally, young couples whose first child has been af-
flicted with a sporadic case of severe disease are eager to
have a healthy child in their next pregnancy [33]. There-
fore, a precise genetic diagnosis is necessary. However,
many MCD candidate genes have been identified, and
Sanger sequencing for predicted causative genes is rather
expensive, laborious, and time-consuming [34]. In com-
parison, in this study, we show that whole-exome se-
quencing is rapid and comprehensive [35]. We further
emphasize that the results of this method provided us
not only with confirmation of the causative genes but
also simultaneously rules out mutations in other candi-
date genes. Therefore, we could completely negate the
contribution of other candidate genes in this patient. In
the future, targeted panel sequencing rather than whole-
exome sequencing may become the standard method
Table 2 Filtered variations
Chromosome Position Region Gene Function dbSNP132 1000G_2010Nov_ALL PolyPhen2 SIFT ref_allele alter_allele Proband Father Mother
chr1 223,175,758 exonic DISP1 nonsynonymous SNV - - 1 0 G A △ × ×
chr1 240,371,141 exonic FMN2 nonsynonymous SNV - - 0.76515 0 C T △ × ×
chr1 247,615,260 exonic OR2B11 Deletion and frameshift > premature
terminal codon
- - A - △ × ×
chr2 189,860,860 exonic COL3A1 nonsynonymous SNV - - 0.784653 0 G A △ × ×
chr2 190,718,672 exonic PMS1 nonsynonymous SNV - - 0.996 0 G A △ × ×
chr6 30,861,156 exonic DDR1 nonsynonymous SNV - - 0.16 0.03 G A △ × ×
chr6 105,824,051 exonic PREP nonsynonymous SNV - - 0.241 0 C T △ × ×
chr8 113,277,807 exonic CSMD3 nonsynonymous SNV - - 0.985 0 C T △ × ×
chr11 124,267,132 exonic OR8B3 nonsynonymous SNV - - 0.275 0.02 A G △ × ×
chr12 49,580,541 exonic TUBA1A nonsynonymous SNV - - 0.777136 0 C G △ × ×
chr16 75,682,281 exonic TERF2IP nonsynonymous SNV - - 0.214 0.02 G A △ × ×
chr17 74,288,545 exonic QRICH2 nonsynonymous SNV - - 0.995 0.01 C G △ × ×
chr19 1,055,329 exonic ABCA7 nonsynonymous SNV - - 0.996 0 A G △ × ×
chr21 10,942,950 exonic TPTE nonsynonymous SNV - - 0.999 0.01 T C △ × ×
chr22 25,011,077 exonic GGT1 nonsynonymous SNV - - 0.318 0.01 C T △ × ×
chrX 153,008,788 exonic ABCD1 nonsynonymous SNV - - 1 0 G A △ × ×





















Figure 3 Results of Sanger sequencing and a map of the identified mutation locus. (A) A Sanger sequencing electropherogram identifying
the missense mutation, c.79G > C (E27Q), is shown. (B) A genome map of the locus surrounding the mutation captured from the UCSC genome
browser is depicted. Because TUBA1A is encoded in an antisense manner, the reverse-complement nucleotide sequence is shown. The affected
amino acid is indicated by a red rectangle. The c.79C residue is conserved among many species as shown.
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candidate genes.
Conclusion
We successfully identified a causative TUBA1A mutation
in a patient with sporadic MCD associated with a sim-
plified gyral pattern by using whole-exome sequencing.
The identified novel mutation (E27Q) was located in the
N-terminal region of the amino acid sequence. Rapid
and comprehensive mutation analysis by using whole-
exome sequencing may be useful for genetic counseling
in sporadic cases of human disorders derived from mul-
tiple candidate genes.
Consent
Written informed consent was obtained from the patient’s
parents for publication of this Case Report and any ac-
companying images. A copy of the written consent is
available for review by the Editor-in-Chief of this journal.
Blood samples from the patient and her biological parents
were obtained with parental consent. This study was ap-
proved by the ethical committee at our institution.Additional files
Additional file 1: Figure S1. Location of the identified TUBA1A
mutation and a comparison of the TUBA1A amino acid sequence with
tubulin family members. (Top) Although many mutations are located in
the C-terminal region, the mutation identified in this patient (E27Q;
indicated by red characters), is located in the N-terminal region. (Bottom)
E27 is conserved among tubulin family member (red rectangle).
Additional file 2: Figure S2. Predicted conformational changes in the
protein structure caused by the identified mutation. The Pôle
Bioinformatique Lyonnais Network Protein Sequence Analysis predicted a
conformational change caused by the E27Q mutation. The location of
the mutation (E27Q) is indicated by a red arrow.
Additional file 3: Figure S3. The predicted secondary structure of
TUBA1A and a simulation of the conformational change. The PSIPRED
Protein Sequence Analysis Workbench predicted no definite change
between the wild-type and mutant protein.Abbreviations
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